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This multicentre study was set up to compare the efficacies of two long-acting &-agonists, oral bambuterol 
(20 mg nocte) and inhaled salmeterol (50,~g b.i.d.), for the treatment of moderate to severe asthmatics who were 
considered to be on optimal steroid/bronchodilator therapy, but continued to have troublesome nocturnal 
symptoms. 
The study was of double-blind, parallel-group design and comprised a 2-week run-in on previous maintenance 
therapy followed by a 6-week study treatment period. There were 117 randomized asthmatic patients aged 20-70 
years (65 women and 52 men with a mean age of 45 and predicted FEV, of 64%), who had been taking 800-2OOOpg 
inhaled steroid and/or up to 20 mg oral steroid per day for at least 4 weeks. They were asked to complete daily 
diary cards, recording morning and evening PEF, daily symptoms, nocturnal awakenings, rescue medication and 
subjective tremor. 
There was a significant increase in both morning and evening PEF respectively, on bambuterol (28 1 min - ‘, 
20 1 min- ‘, PcO.05) and salmeterol (29 1 min - ‘, P<O.OOl; 23 1 min - ‘, IQO.01) when compared with run-in. The 
mean percentage fall in overnight PEF was reduced by 8.3% (P~O.001) on bambuterol and by 6.8% (P<O.OOl) on 
salmeterol. Nocturnal awakenings and daytime symptoms due to asthma were significantly lowered by both 
treatments, as was the consumption of rescue bronchodilator. Tremor scores were very low during both run-in and 
study treatments. No significant treatment difference between bambuterol and salmeterol was detected for any of the 
above variables. 
Once-daily oral bambuterol provides a highly effective alternative to twice-daily inhaled salmeterol for relief of 
nocturnal symptoms in patients with moderate to severe asthma. 
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The nature of asthma as a chronic, persistent inflammatory 
disease of the airways has led to the development and 
widespread use of inhaled steroids, which are currently 
considered to be the most effective and safe drugs for the 
chronic treatment of asthma. However, in patients with 
moderate to severe asthma, adequate control of their 
asthma, particularly nocturnal symptoms, may not be 
achieved even with high doses (over 1000,~g per day) of 
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inhaled steroids. According to recent recommendations (l), 
concomitant treatment with long-acting bronchodilators 
should be considered for those patients and these drugs 
may be given by the oral or inhaled route. Although it is 
recognized that there are advantages in using the inhaled 
route for asthma therapies, there are many patients who do 
not obtain maximum benefit from this type of therapy 
because they cannot use their inhalers efficiently, often 
despite repeated instruction (2). In those and other patients 
who prefer to take tablets, oral medication is preferable. 
Bambuterol and salmeterol are long-acting bronchodilators 
which have been developed for oral and inhaled therapy, 
respectively. Bambuterol is a once-daily oral /&-agonist. It 
is a pharmacologically inactive prodrug of terbutaline, 
which has a high pre-systemic and hydrolytic stability (3). 
Following slow absorption from the gastrointestinal tract, 
it is converted into the active metabolite (45). Clinical 
studies have shown that bambuterol, 10 and 20 mg, admin- 
istered once daily, has a good bronchodilating effect over 
24 h (6) and is associated with less tremor than controlled 
release preparations of salbutamol (7) or terbutaline (8). 
Maximum serum levels after late evening administration 
are achieved during the night or early morning (6), giving 
the drug an ideal pharmacokinetic profile for the treatment 
of nocturnal asthma symptoms (9). Salmeterol is a long- 
acting inhaled /&-agonist with a bronchodilator effect that 
lasts for up to 12 h (10) and it has also been shown to be 
effective for treatment of nocturnal asthma in a dose of 
50 pg b.i.d. (11). 
The primary objective of this study was to compare the 
efficacy of bambuterol and salmeterol in chronic, moderate 
to severe asthmatic patients experiencing nocturnal asthma 
symptoms, despite what we considered to be optimal anti- 
inflammatory treatment with inhaled steroids. This study 
represents the first large controlled comparison of these two 
drugs in patients of this severity. 
PATIENTS AND METHODS 
Patients 
Patients with moderate to severe asthma, as defined in the 
International Consensus Report (l), were recruited for 
study if they fulfilled the following major inclusion criteria. 
1. Men and women aged 18-70 years being treated with a 
constant daily dose of inhaled andlor oral cortico- 
steroids (800-2OOOpg day- ’ of budesonide, flunisolide, 
or beclomethasone via MD1 or 400-2OOOpg day - ’ 
budesonide via Turbuhaler@ (Astro Draco, Lund, 
Sweden) and/or oral prednisolone up to 20 mg day- ’ or 
equivalent), during the month prior to study. 
2. Nocturnal awakening or early awakening due to asthma 
symptoms which required rescue medication at least 
once during a 2-week run-in period. 
3. 2 15% fall in overnight PEF during 3 out of the last 7 
days of run-in. 
4. FEV, to be 40-85% of predicted normal value at visit 1. 
Patients who had received parenteral depot cortico- 
steroid during the 3 months prior to study or who had an 
exacerbation of their asthma during the 4 weeks prior to 
entry requiring additional oral/parenteral steroids or 
nebulised &agonists were excluded from the study, as were 
patients with intercurrent respiratory infection, significant 
seasonal allergy, or any significant disease other than 
asthma. 
STUDY DESIGN AND TREATMENT 
The study was performed in accordance with the 
Declaration of Helsinki and the protocol was approved by 
the Comite Consultatif de Protection des Personnes dans 
la Recherche Biomedicale de Lille before the study 
commenced. 
This was a double-blind, randomized, multicentre study 
with two parallel treatment groups. There was an initial 
2-week run-in period during which patients completed diary 
cards whilst on their standard medication. They were then 
randomized (in blocks of four at each centre) to receive 
double-dummy treatment with either: active bambuterol 
tablets, 10 mg (one-half 20 mg tablet) once daily at bedtime 
for 7 days increasing to 20 mg (one tablet) at bedtime for 
the remaining 5 weeks, plus placebo salmeterol p-MDI, 2 
puffs morning and evening (12 h apart) for 6 weeks; or 
active salmeterol p-MD& 50,~g (2 puffs) morning and 
evening (12 h apart) for 6 weeks, plus placebo bambuterol 
at bedtime, half a tablet for 1 week and one tablet for the 
remaining 5 weeks. 
Active treatment started with an evening dose at visit 2 
and no dose adjustments were permitted during the study. 
Patients returned to the clinic for visit 3 after 3 weeks and 
for visit 4 after 6 weeks of active treatment. 
Concomitant medication 
Concomitant treatment with short-acting inhaled 
bronchodilators was permitted for rescue therapy during 
the study, but preferably not within 6 h of PEF measure- 
ment (salmeterol was not to be used as a rescue therapy). 
Regular inhaled or oral therapy with corticosteroids in the 
doses defined in the inclusion criteria was permitted, as 
was regular treatment with disodium cromoglycate or 
nedocromil sodium (inhaled, nasal or ocular), nasal 
corticosteroids, slow-release and rectal theophylline or 
antihistamines. 
If an exacerbation of asthma occurred during the study, 
additional treatment with inhaled or nebulised short-acting 
bronchodilators or parenteral bronchodilators was permit- 
ted for up to 4 days, but no longer. If a second exacerbation 
occurred, the patient was excluded from the study. 
No /I-blockers were permitted during the study. Any 
other medication considered necessary for the patient’s 
welfare was to be given at the investigator’s discretion. 
CLINICAL AND LABORATORY ASSESSMENT 
At the clinic 
At visit 1 patients were informed about the study and asked 
to give their written informed consent to participate. 
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Details of demography (age, sex, height, weight, ethnic 
group), current medication, duration of asthma and 
smoking habits were recorded and entry criteria were 
confirmed. Baseline and post-bronchodilator FEV, (15-30 
min after inhalation of terbutaline sulphate 1.0 mg, via 
Turbuhaler@) were measured and calculated as % of nor- 
mal predicted. These measurements were to be done 
between 6 and 72 h after the patient had taken a broncho- 
dilator, depending on the type taken pre-entry (i.e. at least 
6 h after a short-acting inhaled &agonist and 72 h after 
salmeterol). Patients were shown how to use a PEF meter 
(Vitalographa, Vitalograph Ltd., Bucks, U.K.) and were 
issued with diary cards for recording of lung function, 
symptoms and sleep disturbance daily at home. Their 
pMDI inhalation technique was checked and if there was 
any doubt about their competence, they were provided with 
a spacer (Volumatic@, Laboratories Glaxo, Paris, France) 
for use with the study pMD1. 
At visit 2 (end of 2-week run-in period), patients were 
asked whether they had experienced any adverse events and 
they completed a questionnaire on nocturnal asthma 
symptoms. 
After 3 weeks of study medication (visit 3), patients 
returned to the clinic for assessment of compliance, includ- 
ing a check on their pMDI technique, and to record any 
adverse events. 
At the end of the 6-week study period (visit 4) diary 
cards were collected along with any unused medication, any 
adverse events were recorded and patients were asked to 
complete a second questionnaire about nocturnal asthma 
symptoms. 
Af home 
Diary cards were completed twice daily. In the morning, 
PEF (best of three blows, performed no longer than 10 
minutes after awakening) and awakening during the night 
due to asthma (Yes or No) were recorded along with details 
of rescue bronchodilator use. In the evening, PEF (best of 
three blows, before medication and, if possible, at least 6 h 
after the last inhalation of short-acting bronchodilator) and 
asthma symptoms and tremor during the day (scaled from 
O-3, where O=no symptoms and 3 =severe symptoms) were 
recorded along with details of rescue bronchodilator use. 
Staatistical analyses 
It was calculated that, with a sample size of 50 patients 
in each treatment group, there was an 80% power (at the 
5% significance level) of detecting a true difference of 
221 min-’ between treatments. The primary efficacy vari- 
able was morning PEF change from baseline during treat- 
ment period, expressed as absolute value (1 min - ‘). Mean 
baseline values were calculated over the last 2 weeks of the 
run-in period. Regarding the treatment period, for the 
efficacy variables, mean values were calculated over the last 
4 weeks. This rule was adopted because the full dose of 
bambuterol was given after 1 week of treatment, as recom- 
mended. For the tremor variable, mean values were 
calculated over the whole treatment period in order not to 
exclude the first days of treatment. 
Simple comparisons were performed for categorical data 
using the chi-square test and for continuous data using 
either the Student’s t-test for normally distributed variables 
or the Mann-Whitney U-test for variables which were not 
normally distributed. 
Comparisons between treatment groups of FEV, and 
PEF were performed using the Student’s t-test (for absolute 
values), and the Mann-Whitney U-test (for percentages). 
The Mann-Whitney U-test was also used for continuous 
not normally distributed variables and ordinal variables: 
number of days on study medication, daily dose of medi- 
cation, nocturnal awakenings, intake of &agonists, symp- 
tom scores, symptom-free days and tremor scores. 
Regarding the primary variable, a multivariate analysis was 
also performed using the variancelcovariance technique 
with the PROC GLM of the SAS software (version 6.08, 
SAS Institute Inc., Cary, NC, U.S.A.). 
Results 
A total of 117 patients were randomized to study 
treatments, 57 to receive bambuterol and 60 to receive 
salmeterol. Their demographic and baseline lung function 
data are presented in Table 1. The two treatment groups 
were similar with respect to age, physical characteristics and 
intake of inhaled or oral steroids. Both (bambuterol and 
salmeterol groups, respectively) had similar baseline lung 
function (64 and 64.6% predicted FEV,) and demonstrated 
similar mean reversibility to &agonist (11 and 13%). 
The mean duration of asthma was slightly longer in the 
bambuterol group (18 years) compared with the salmeterol 
group (14.8 years), but the numbers of patients on oral 
steroids were similar (8 and 9 respectively). One patient 
on bambuterol was taking oral steroids without any 
concomitant inhaled steroids. 
Twenty-one patients discontinued the study prematurely, 
10 during bambuterol and 11 during salmeterol treatment, 
for reasons summarized in Table 2. As a result, three 
patients were excluded from the safety and efficacy analyses 
(one bambuterol, two salmeterol). A further nine patients 
were excluded from the efficacy analysis for the follow- 
ing reasons: treatment period less than 14 days (seven 
bambuterol, one salmeterol); one (bambuterol) patient 
received both active medications. The time to discontinu- 
ation tended to be shorter in the bambuterol than in the 
salmeterol group. 
CLINICAL EFFICACY 
Lung function 
Lung function (PEF) data during run-in and active treat- 
ment are summarized in Table 3. In both treatment groups, 
there were similar increases in morning and evening PEF 
from run-in to active treatment and when these were 
compared between the groups, no significant differences 
were detected (morning PEF, P~0.86; evening PEF, 
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TABLE 1. Demographic and disease characteristics at entry 
Bambuterol 
(n=57) 
Salmeterol 
(n=60) 
Gender: F/M 32125 33127 
Age in years: mean (range) 45 (20-69) 46 (21-70) 
Weight in kg: mean (SD) 72 (18) 72 (15) 
Height in cm: mean (SD) 166 (9) 168 (9) 
Non-smokers 38 44 
Current/past smokers 4115 2114 
Duration of asthma in yrs: mean (SD) 18.0 (13.2) 14.8 (11.4) 
Daily dose inhaled steroids in mg: mean (SD) 1.21 (0.45) 1.22 (0.41) 
No. of patients treated with oral steroids 8 9 
No. of patients treated with theophylline 13 
% predicted FEV,: mean (SD) 64.1 (11.7) 64.6’;3.5) 
Reversibility to bronchodilator: as % predicted FEV,*: mean (SD) 11.2 (8.8) 12.5 (9.8) 
*l.O mg terbutaline sulphate from Bricanyl@ Turbuhaler@. 
TABLE 2. Reasons for premature discontinuation of study 
Reason* 
Bambuterol 
(n= 10) 
Salmeterol 
(n=ll) 
Adverse events* 7 2 
Asthma deterioration 2 5 
Lost to follow-up 1 3 
Patient request 0 1 
*Irrespective of a causal relationship to study drug. 
PzO.73). The changes in morning PEF were highly sig- 
nificant, being 28 1 min- ’ (P<O.OOl) for bambuterol and 
29 1 min - ’ (P<O.OOl) for salmeterol. Smaller changes in 
evening PEF were observed, namely 20 1 min- ’ (PcO.05) 
for bambuterol and 23 1 min- ’ (PcO.01) for salmeterol. 
Diurnal variation in PEF 
Mean percentage fall in overnight PEF was calculated for 
run-in and active treatment periods. During both active 
treatments, there was a significant reduction in the over- 
night fall in PEF compared with run-in from 16.1 to 7.8% 
for bambuterol (P<O*OOl) and from 13.4 to 6.6% for 
salmeterol (P<O.OOl), respectively, with no significant 
difference between the treatment effects (P=O.47). 
Nocturnal and dayfime symptoms case), but no significant difference between the treatments 
(Fig. 1). 
Nocturnal symptoms were assessed according to the Daytime symptoms were assessed according to their 
number of times a patient awoke during the night or early severity and followed a similar pattern to nocturnal 
morning due to asthma. During the run-in, patients in each symptoms, i.e. there was a significant fall in symptom scores 
group awoke approximately every other night due to their from the run-in period to active treatment with bambuterol 
asthma. There was a significant decrease in the number of (P<O.OOl) or salmeterol (P<O*OOl), but no significant dif- 
awakenings during each active treatment (PcO.01 in each ference between the treatments (Table 3). The proportion of 
4-l F-7 
I, 
FIG. 1. Nocturnal awakenings. Mean percentage of nights 
(with SE bars) on which nocturnal awakening due to 
asthma occurred during run-in 0, bambuterol treatment 
q , or salmeterol treatment n . *=P<O.Ol. 
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TABLE 3. Lung function and symptoms at baseline and during treatment 
Bambuterol Salmeterol 
(n=48) (n=57) 
Comparison 
between two 
groups 
(P-value) 
Morning PEF in 1 min -I: mean (SD) 
Run-in 280 (73) 
Active treatment 307 (80) 
Change from run-in to active 28 (51) 
Evening PEF in 1 min - r : mean (SD) 
Run-in 305 (71) 
Active treatment 324 (80) 
Change from run-in to active 20 (53) 
Daytime symptom score: mean (SD) 
Run-in 1.09 (0.59) 
Active treatment 0.71 (0.63) 
Change from run-in to active - 0.38 (0.59) 
Symptom-free days in %: mean (SD) 
Run-in 22 (28) 
Active treatment 45 (41) 
Change from run-in to active 23 (40) 
Rescue &agonist: mean puffs (SD) day/night 
Run-in 3.18 (2.50)/1.62 (1.52) 
Active treatment 2.56 (2.27)/1.15 (1958) 
Change from run-in to active - 0.65 (1.90)/ - 0.46 (1.49) 
304 (84) 0.12 
333 (101) 0.15 
29 (52) 0.86 
325 (90) 0.21 
348 (106) 0.21 
23 (53) 0.73 
1.07 (0.69) 0.96 
0.8 1 (0.63) 0.47 
- 0.27 (0.55) 0.44 
27 (37) 0.76 
41 (38) 0.62 
14 (30) 0.55 
3.21 (2.31)/1.64 (1.46) 0~74/0~90 
2.39 (2.74)/l .06 (1.64) 0.3410.69 
- 0.80 (2.05)/ - 0.59 (1.11) 0.2310.36 
symptom-free days doubled during each active treatment 
period, from approximately 25 to 50% (Table 3). 
Consumpfion of ‘rescue’ inhaled &,-agonist 
Consumption of ‘rescue’ inhaled short-acting &-agonist 
during the night (mean number of puffs recorded in diary 
cards), was significantly lower during bambuterol treatment 
than run-in (1.15 vs. 1.62, PcO.05). This was also true for 
salmeterol (1.06 W. 1.64, P<O.OOl), with no significant 
difference between the treatments. Similarly, daytime 
intake of rescue medication was significantly lower during 
salmeterol treatment (2.39 vs. 3.21, P<O.OOl) and lower 
during bambuterol treatment (2.56 vs. 3.18, n.s.), with no 
significant difference between the treatments. 
SAFETY AND TOLERABILITY 
Adverse events were reported in 33 out of 56 patients in 
the bambuterol group and 28 out of 58 patients in the 
salmeterol group. The most frequent events involved 
the respiratory system (21 bambuterol, 11 salmeterol). 
Pharmacologically predictable adverse events were as 
follows: headache (six bambuterol, two salmeterol); tremor 
(three bambuterol, three salmeterol); cramps (two 
bambuterol); and tachycardia and/or palpitation (three 
bambuterol, one salmeterol). Seven patients were 
prematurely discontinued from the study due to an asthma 
exacerbation (two bambuterol, five salmeterol): in four 
cases (one bambuterol, three salmeterol) asthma exacer- 
bation resulted in hospitalization. In addition, five patients 
were withdrawn from the study due to adverse events 
possibly related pharmacologically to the study drugs: four 
in the bambuterol group (one headache; one insomnia; 
one mental excitation; one facial flush) and one in the 
salmeterol group (tremor). 
Mean tremor scores (SD) from patient diary cards were 
very low during the run-in period, 0.21 (0.53) in the 
bambuterol group and 0.31 (0.58) in the salmeterol 
group respectively. They remained very low during 
both bambuterol [0.16 (0.34)] and salmeterol [0.25 (0.47)] 
treatments. 
Discussion 
The patients in this study were considered to have moderate 
to severe asthma and had been on combined treatment with 
bronchodilators and inhaled or oral glucocorticosteroids 
which was thought to be optimal for their condition. They 
still complained of troublesome nocturnal symptoms, how- 
ever. The present results indicate that the bambuterol and 
salmeterol groups obtained similar benefit from their treat- 
ment in terms of improvement in PEF and symptoms and 
reduction in overnight PEF dipping. As a result, patients 
had fewer disturbed nights due to their asthma. Although 
FEV, and reversibility were similar at study entry, mean 
morning and evening PEF during run-in tended to be lower 
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in the bambuterol than in the salmeterol group. However, 
this difference did not reach statistical significance. More- 
over, a complementary analysis showed that the baseline 
value of morning PEF had no influence on its change from 
baseline during treatment. All other parameters reflecting 
asthma severity, as shown in Tables 1 and 3, were very 
similar. Therefore it is unlikely that this random difference 
in baseline had any effect on the response to therapy. 
In patients of this severity, some of whom were on oral 
steroids in addition to their high-dose inhaled steroid 
therapy, it is preferable not to increase the steroid intake 
further. A recent study by Greening et al. (12) has shown 
that further increases in inhaled steroid therapy may, in any 
case, be less effective than the addition of a long-acting 
bronchodilator such as salmeterol. The results of our study 
confirm the effectiveness of twice-daily salmeterol in more 
severe asthmatics, but also indicate that similar efficacy can 
be obtained from a single daily tablet of bambuterol. The 
dose of bambuterol selected for our study was based on the 
clear dose-response in bronchodilation obtained in a study 
with 10 and 20 mg nocte (13). In more severe asthmatics, 
20 mg nocte is thought to be the optimal dose. The dose of 
salmeterol selected was the standard prescribed dose shown 
to have a duration of 12 h (10). 
The use of P,-agonists for nocturnal symptoms has, in the 
past, been restricted in some patients due to unwanted 
tremor effects. Although the controlled-release preparations 
of terbutaline and salbutamol went some way towards 
solving this problem, there was room for improvement. 
Our results indicate that the addition of bambuterol or 
salmeterol to ‘optimal’ therapy can improve lung function 
and provide excellent relief from nocturnal symptoms with- 
out producing major tremor. To our knowledge, this is the 
first large controlled comparison of bambuterol and 
salmeterol and we conclude that either drug is safe and 
effective for the control of nocturnal symptoms in moderate 
to severe asthmatic patients. 
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